NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC
The Screen · Healthcare · Medical Devices
Glaukos Corporation
GKOS · the NYSE · USD · Market cap $9.9B · 1,094 employees
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price167.25 USD
Fair value103.05
Ethical score70.0/100
Our investment reviews on this name
2026-08-30Read Accumulation181.39-7.8% to today
2026-07-31Read Markup168.52-0.8% to today
2026-07-02Read Distribution126.81+31.9% to today
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Glaukos Corporation holds its Markdown at $167.25. The statistical read favours the sellers, held for 20 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 20 days
Price at the screen
$167.25
Valuation
N/A trailing · 331.63 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.77
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
11.63%
Below 33%
Interest-bearing debt is just 11.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
21.04%
Below 33%
Cash held in interest-bearing accounts and securities is 21.0% of assets, under the one-third limit.
Pass
Receivables
22.32%
Below 49%
Money owed to the company is 22.3% of assets, under the 49% limit.
Pass
Revenue purity
2.11%
Below 5%
Only 2.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. The price runs 38.4% above the base estimate.
Third-party analyst targets: 13 covering, consensus Strong Buy. The average target sits +17% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Glaucoma device firm priced far beyond its worth
Picture a patient in need of a micro stent to ease glaucoma pressure. Glaukos builds those implants and revenue is climbing 41 percent, yet the shares sit at 157 dollars while our fair value sits at 88.
Why we pass. The forward multiple reaches 370 times earnings even as profit margins sit at minus 34 percent and return on equity at minus 26 percent. The ethical screen clears but that does not close a 44 percent valuation gap.
Risk sits in the ongoing losses and the unknown moat in a crowded eye care field. Analyst targets may sit higher still, yet the stretched price leaves scant margin if growth slows. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GKOS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it strong buy, with a mean price target of $154.
2026-07-31Markup · changed$168.52+32.9%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 32.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it strong buy, with a mean price target of $154.
2026-07-18Distribution$126.81+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (12 analysts) rates it strong buy, with a mean price target of $154.
2026-07-03Distribution$126.81+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$126.81Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
